NCT04157907

Brief Summary

Borderline personality disorder (BPD) is a pervasive mental disorder characterized by emotional instability, self-destructive behavior, identity problems and unstable relationships. Persons with this disorder usually experience significant distress in terms of depression, anxieties, suicidal behavior, and difficulties in close relationships as well as with work- and social functioning. Recent research has found the prognosis of BPD to be better than previously assumed, and many patients improve from treatment. Mentalization based therapy (MBT) is a specialized evidenced based therapy for patients with BPD. Like for other specialized treatments for this disorder, the outcome of therapy is typically variable, some patients respond well to treatment, whereas others respond less. It is therefore important to understand how treatment works in order to improve therapies and tailor treatment to individual patients. Mentalizing is the ability to understand ourselves and others in terms of mental states, like intentions, feelings, desires, attitudes, and so on, or briefly; the ability to mind own and other's minds. Impaired mentalizing capacity is an assumed core aspect of BPD, underlying many of the symptoms of this disorder. MBT focuses on the patients mentalizing difficulties and is typically offered as a long-term combined treatment program comprising individual and group therapy, as well as psychoeducation. Several studies have documented positive effects of MBT in terms of reduced suicidal behavior, symptoms, interpersonal problems, medication, and health service use. It is assumed that such clinical improvement is made possible by helping the patients to develop their mentalizing abilities. Yet, no study has investigated whether patients' mentalizing capacity changes during MBT, or to what degree outcome of MBT is mediated by improved mentalizing. Mentalizing is, however, a complex phenomenon and difficult to measure. Research in this area has been hampered by a lack of suitable methods. Mentalizing is usually operationalized as Reflective Functioning (RF) assessed by the RF Scale. The gold standard is to apply the RF Scale on the Adult Attachment Interview. However, this is a time consuming and costly method, and there is a need for testing other methods as well. The overall aim of the project is to study treatment processes in MBT for patients with BPD. It focuses on patients' mentalizing difficulties before, during and at the end of therapy. Mentalizing is assessed using different methods. Our main research questions are:

  1. 1.To what degree does patients' level of RF change during MBT?
  2. 2.Is there a relationship between RF and outcome of MBT?
  3. 3.What is the relationship between RF and therapy processes in MBT?
  4. 4.Is it possible to identify in-session processes that promote mentalizing?
  5. 5.What is the clinical utility of various methods of RF assessment?

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Nov 2019

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 1, 2019

Completed
Same day until next milestone

Study Start

First participant enrolled

November 1, 2019

Completed
7 days until next milestone

First Posted

Study publicly available on registry

November 8, 2019

Completed
5.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 28, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 28, 2025

Completed
Last Updated

November 8, 2019

Status Verified

November 1, 2019

Enrollment Period

5.3 years

First QC Date

November 1, 2019

Last Update Submit

November 6, 2019

Conditions

Outcome Measures

Primary Outcomes (17)

  • Work and Social Adjustments Scale, WSAS, change during treatment and 3 months follow-up

    Work and social adaption

    6, 12, 18, 24, 30 and 36 months, and 3 months follow-up

  • Global Assessment of Functioning, GAF, change during treatment and 3 months follow-up

    psychosocial functioning

    6, 12, 18, 24, 30 and 36 months, and 3 months follow-up

  • Patient Health Questionnaire, PHQ-9, change during treatment and 3 months follow-up

    depression

    6, 12, 18, 24, 30 and 36 months, and 3 months follow-up

  • Patient Health Questionnaire, GAD-7, change during treatment and 3 months follow-up

    anxiety

    6, 12, 18, 24, 30 and 36 months, and 3 months follow-up

  • Self-harm, self-report, change during treatment and 3 months follow-up

    Self-harm

    6, 12, 18, 24, 30 and 36 months, and 3 months follow-up

  • Suicide attempts, self-report, change during treatment and 3 months follow-up

    Suicide attempts

    6, 12, 18, 24, 30 and 36 months, and 3 months follow-up

  • Circumplex of Interpersonal Problems, CIP, change during treatment and 3 months follow-up

    interpersonal problems

    6, 12, 18, 24, 30 and 36 months, and 3 months follow-up

  • Severity Index of Personality Problems, SIPP-118, change during treatment and 3 months follow-up

    personality functioning

    6, 12, 18, 24, 30 and 36 months, and 3 months follow-up

  • Level of Personality Functioning Scale, LPFS BF, change during treatment and 3 months follow-up

    personality functioning

    6, 12, 18, 24, 30 and 36 months, and 3 months follow-up

  • Difficulties in Emotion Regulation Scale, DERS, change during treatment and 3 months follow-up

    emotional regulation

    6, 12, 18, 24, 30 and 36 months, and 3 months follow-up

  • Toronto Alexithymia Scale, TAS-20, change during treatment and 3 months follow-up

    alexithymia

    6, 12, 18, 24, 30 and 36 months, and 3 months follow-up

  • Reflective functioning based on AAI, change from baseline to 3 months follow-up

    reflective functioning

    3 months follow-up

  • Reflective functioning based on the mentalization breakdown interview, change during treatment and 3 months follow-up

    reflective functioning

    6, 12, 18, 24, 30 and 36 months, and 3 months follow-up

  • Reflective functioning based on therapy sessions, change during treatment

    reflective functioning

    6, 12, 18, 24, 30 and 36 months

  • Months in work or studies, self report, change during treatment and 3 months follow-up

    work functioning

    6, 12, 18, 24, 30 and 36 months, and 3 months follow-up

  • Experiences in Close relationships, ECR, change during treatment and 3 months follow-up

    attachment

    6, 12, 18, 24, 30 and 36 months, and 3 months follow-up

  • Suicide ideation, change during treatment and 3 months follow-up

    Suicide ideation

    6, 12, 18, 24, 30 and 36 months, and 3 months follow-up

Secondary Outcomes (7)

  • Substance use (from AUDIT and DUDIT), change during treatment and 3 months follow-up

    6, 12, 18, 24, 30 and 36 months, and 3 months follow-up

  • EuroQoL, EQ-5D, change during treatment and 3 months follow-up

    6, 12, 18, 24, 30 and 36 months, and 3 months follow-up

  • Modified Overt Aggression Scale (selected items), change during treatment and 3 months follow

    6, 12, 18, 24, 30 and 36 months, and 3 months follow-up

  • Working Alliance Inventory, WAI, change during treatment

    6, 12, 18, 24, 30 and 36 months

  • Group Questionnaire, GQ, change during treatment

    6, 12, 18, 24, 30 and 36 months

  • +2 more secondary outcomes

Study Arms (1)

Patients with borderline personality disorder

Patients with borderline personality disorder included in the MBT program

Behavioral: Mentalization based therapy

Interventions

Mentalization based therapy is a specialized treatment for patients with borderline personality disorder. The treatment program combines individual and group therapy, as well as psychoeducation

Patients with borderline personality disorder

Eligibility Criteria

Age18 Years - 40 Years
Sexall
Age GroupsAdult (18-64)
Sampling MethodProbability Sample
Study Population

Patients with borderline personality disorder or significant borderline traits, who are treated in the MBT program at the Personality Outpatient Unit, Oslo University Hospital (OUH).

You may qualify if:

  • \- Borderline personality disorder or significant borderline traits

You may not qualify if:

  • patients with psychotic disorders as their main problem
  • Asperger's syndrome/autism spectrum disorders
  • low IQ
  • unregulated bipolar I disorders as their main problem

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Personality Outpatient Unit, Section of Personality Psychiatry, Clinic for Mental Health and Addiction, Oslo University Hospital

Oslo, 4959 Nydalen, Norway

RECRUITING

Related Publications (1)

  • Ulvestad DA, Johansen MS, Kvarstein EH, Pedersen G, Wilberg T. Minding mentalizing - convergent validity of the Mentalization Breakdown Interview. Front Psychiatry. 2024 Jun 21;15:1380532. doi: 10.3389/fpsyt.2024.1380532. eCollection 2024.

MeSH Terms

Conditions

Borderline Personality Disorder

Interventions

Mentalization-Based Therapy

Condition Hierarchy (Ancestors)

Personality DisordersMental Disorders

Intervention Hierarchy (Ancestors)

PsychotherapyBehavioral Disciplines and Activities

Study Officials

  • Theresa Wilberg, professor

    Department of Research and Development, Oslo University Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Theresa Wilberg, MD PhD

CONTACT

Elfrida Hartveit Kvarstein, MD PhD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
senior consultant and professor

Study Record Dates

First Submitted

November 1, 2019

First Posted

November 8, 2019

Study Start

November 1, 2019

Primary Completion

February 28, 2025

Study Completion

February 28, 2025

Last Updated

November 8, 2019

Record last verified: 2019-11

Data Sharing

IPD Sharing
Will not share

Locations